Related Experiment Videos
Spondyloarthritis: update on pathogenesis and management
John D Reveille1, Frank C Arnett
1Division of Rheumatology, Department of Internal Medicine, The University of Texas-Houston Health Science Center, USA. john.d.reveille@uth.tmc.edu
The American Journal of Medicine
|June 1, 2005
Summary
Advances in understanding ankylosing spondylitis (AS) and spondyloarthritis (SpA) involve genetic factors like HLA-B27 and gut inflammation. Novel treatments, including TNF blockers, offer hope but require careful patient selection due to cost and side effects.
Area of Science:
- Rheumatology and Immunology
- Genetics and Molecular Biology
Background:
- Ankylosing spondylitis (AS) and spondyloarthritis (SpA) are inflammatory conditions with complex etiologies.
- Genetic factors, including human leukocyte antigen (HLA)-B27 and other major histocompatibility complex (MHC) genes, play a role in disease susceptibility and severity.
- Emerging evidence suggests a role for intestinal inflammation and gut barrier dysfunction in the pathogenesis of AS and enteropathic arthritis.
Purpose of the Study:
- To review recent advancements in understanding the genetic and environmental factors contributing to spondyloarthritis.
- To discuss the evolving mechanisms of HLA-B27 in disease pathogenesis.
- To summarize current and emerging therapeutic strategies for spondyloarthritis, focusing on the impact of biologic agents.
Main Methods:
- Review of current literature on the genetics, pathogenesis, and treatment of ankylosing spondylitis and spondyloarthritis.
- Analysis of the proposed mechanisms of HLA-B27 involvement, including antigen presentation, molecular misfolding, and autoimmunity.
- Evaluation of the efficacy and limitations of various treatment modalities, from conventional therapies to novel biologic agents.
Main Results:
- Genetic predisposition to spondyloarthritis is linked to HLA-B27 and other genomic regions.
- Pathogenesis may involve HLA-B27 misfolding, impaired bacterial clearance, autoimmunity, and gut inflammation disrupting the gut:blood barrier.
- Tumor necrosis factor (TNF) blockers have shown significant promise in managing peripheral arthritis, enthesitis, and axial disease in spondyloarthritis, often outperforming traditional treatments.
Conclusions:
- Significant progress has been made in understanding the multifactorial etiology of spondyloarthritis.
- TNF blockers represent a major therapeutic advance, offering relief for refractory symptoms, but their use necessitates careful consideration of cost and side effect profiles.
- Further research is needed to refine treatment guidelines and optimize patient selection for biologic therapies in spondyloarthritis.